Share chart Ionis Pharmaceuticals
Main settings
Grade
Underestimation
| Title | Value | Grade |
| P/S | 7.4 | 1 |
| P/BV | 8.87 | 1 |
| P/E | -13.64 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -15.15 | 0 |
| ROE | -93.1 | 0 |
| ROIC | -0.1 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0.625 | 6.25 |
| Average dividend growth | -91.67 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -2.98 | 10 |
| Debt/Ratio | 0.4716 | 10 |
| Debt/Equity | 4.11 | 2 |
Growth impulse
| Title | Value | Grade |
| Revenue, bln, % | -3.27 | 0 |
| Ebitda, % | 176.21 | 10 |
| EPS, % | -13.01 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 62.97 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 61.01 $ | 0 $ | 0 $ | +3.21 % | 0 % | 0 % |
| Month | 42.75 $ | 61 $ | 64.4 $ | +47.3 % | 0 % | 0 % |
| Three month | 39.8 $ | 40.69 $ | 64.4 $ | +58.22 % | 0 % | 0 % |
| Half a year | 31.15 $ | 26.71 $ | 64.4 $ | +102.15 % | 0 % | 0 % |
| Year | 49.25 $ | 25.51 $ | 64.4 $ | +27.86 % | 0 % | 0 % |
| 3 years | 33.08 $ | 25.51 $ | 64.4 $ | +90.36 % | 0 % | 0 % |
| 5 years | 62.68 $ | 25.11 $ | 64.4 $ | +0.4627 % | 0 % | 0 % |
| 10 years | 12.64 $ | 21.36 $ | 85.62 $ | +398.18 % | 0 % | 0 % |
| Year to date | 35.63 $ | 25.51 $ | 64.4 $ | +76.73 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Direxion mRNA ETF | 4.07 | 0 | 0.65 |
| Future Tech ETF | 0.61003 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 0.61003 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Growth ETF | 0.25021 | 519.61 | 0.06 |
| Fidelity Growth Opportunities ETF | 0.2118 | -19.3 | 0.38 |
| iShares Morningstar Small-Cap ETF | 0.12527 | 270.73 | 0.25 |
| 0.98 | 207.77 | 0.34 |
|---|
Similar companies
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Darren Gonzales | Chief Accounting Officer & Senior VP | N/A | |
| Dr. Brett P. Monia Ph.D. | Founder, CEO & Director | 1.71M | 1961 (64 years) |
| Ms. B. Lynne Parshall Esq., J.D. | Director | 334.64k | 1954 (71 year) |
| Dr. C. Frank Bennett BSc, Ph.D. | Executive VP & Chief Scientific Officer | 651.64k | 1957 (68 years) |
| Mr. D. Wade Walke Ph.D. | Senior Vice President of Investor Relations | N/A | |
| Ms. Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive VP of Finance & CFO | 1.02M | 1962 (63 years) |
| Dr. Richard S. Geary Ph.D. | Executive VP & Chief Development Officer | 946.26k | 1958 (67 years) |
| Ms. Hayley Soffer | Vice President of Corporate Communications | N/A | |
| Dr. Eric E. Swayze Ph.D. | Executive Vice President of Research | 1966 (59 years) | |
| Mr. Patrick R. O'Neil Esq. | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | 1974 (51 year) |
About company
Website: http://www.ionispharma.com
About Ionis Pharmaceuticals
Ionis Pharmaceuticals - биотехнологическая компания, базирующаяся в Карлсбаде, Калифорния, которая специализируется на открытии и разработке терапевтических средств, нацеленных на РНК. У компании есть 3 коммерчески одобренных препарата: Спинраза (Нусинерсен), Тегседи (Инотерсен) и WAYLIVRA, а также 4 препарата в основных исследованиях: томинерсен от болезни Хантингтона, тоферсен от SOD1-ALS, AKCEA-APO (a) -LRx от сердечно-сосудистых заболеваний. и AKCEA-TTR-LRx для всех форм амилоидоза TTR.
До декабря 2015 года компания носила название Isis Pharmaceuticals.
Компания была основана в 1989 году как Isis Pharmaceuticals Стэнли Т. Крук, бывшим руководителем отдела исследований GlaxoSmithKline, с целью коммерциализации антисмысловой терапии.
